Loading
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Previous close
$15.04
−$0.25 · -1.64%
Regular session · ET · Market data may be delayed.
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Day range
Current $15.04
52-week range
Current $15.04
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
29
Expensive
Sentiment
36
Bearish
Risk
46
Elevated Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Day range
Current $15.04
52-week range
Current $15.04
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | — | — | 4.58M USD |
| Gross profit | — | — | — | — | −4.58M USD |
| Research and development | 221.18M USD | 189.45M USD | 174.96M USD | 126.53M USD | 80.65M USD |
| Selling, general, and administrative | 98.74M USD | — | — | — | 36.26M USD |
| Operating expenses | 319.92M USD | 261.63M USD | 234.77M USD | 177.08M USD | 116.91M USD |
| Interest income | 13.63M USD | 21.12M USD | 23.36M USD | 10.01M USD | 390K USD |
| Interest expense | 8.86M USD | 7.89M USD | 6.66M USD | 4.16M USD | 2.22M USD |
| Depreciation and amortization | 3.33M USD | 5.93M USD | 5.08M USD | 2.45M USD | 4.58M USD |
| Operating income | −319.92M USD | −261.63M USD | −234.77M USD | −177.08M USD | −121.48M USD |
| Net income | −313.94M USD | −247.3M USD | −215.79M USD | −174.28M USD | −118.04M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$18.67
24.14% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI44.79M0.39%11.49B USD0.35%$163.81-0.35%
iShares Russell 2000 ETFIWM31.2M0.04%80.51B USD0.19%$296.01+0.28%
Vanguard Morningstar Total Stock Market ETFVTI22.09M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 Value ETFIWN11.32M0.08%14.61B USD0.24%$224.62+0.40%
iShares Biotechnology ETFIBB10.14M0.09%10.73B USD0.44%$211.92-0.88%
Vanguard Extended Market ETFVXF9.67M0.01%93.7B USD0.05%$242.66+0.14%
Invesco Dorsey Wright Healthcare Momentum ETFPTH7.02M2.46%285.5M USD0.74%$61.1284-0.38%
Schwab U.S. Small-Cap ETFSCHA5.44M0.02%22.93B USD0.03%$34.55+1.01%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFInvesco Dorsey Wright Healthcare Momentum ETFPTHSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
